Novavax, Inc. (NASDAQ:NVAX), announced on Thursday that the Biomedical Advanced Research and Development authority extended the base period of performance of a contract with the pharmaceutical company for its recombinant seasonal and pandemic influenza vaccines. Novavax, Inc. (NASDAQ:NVAX) stock performance was 1.27% in last session and finished the day at $6.38. Traded volume was 13,436,282 million shares in the last session and the average volume of the stock remained 5.16 million shares. The beta of the stock remained 2.14. Novavax, Inc. (NASDAQ:NVAX) insider ownership is 0.10%.

Thomson Reuters/Verus upgraded shares of VIVUS (NASDAQ:VVUS) from a sell rating to a hold rating in a report released on Monday, Analyst Ratings Net reports. VIVUS, Inc. (NASDAQ:VVUS) rose 1.15 percent to $6.16 yesterday on volume of 13.26 million shares. The intra-day range of the stock was $6.09 to $6.34. VIVUS, Inc. (NASDAQ:VVUS) has a market capitalization of $622.67 million.

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has announced Mark P. Carthy its latest director. The company issued a press release Monday that Mr. Carthy was joining its board of directors. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)’s stock on Mar 4, 2014 reported a increase of 3.52% to the closing price of $1.47. Its fifty two weeks range is $0.28 -$1.85. The total market capitalization recorded $68.68 million. The overall volume in the last trading session was 12,763,745 million shares. In its share capital, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has 130.47 million outstanding shares.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Feb. 25 reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. On Tuesday, shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) advanced 1.98% to close the day at $8.75. Company return on investment (ROI) is -220.70% and its monthly performance is recorded as 18.40%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) quarterly revenue growth is 80.79%.